毕得医药(688073) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for the third quarter reached ¥351,584,503.91, representing a year-on-year increase of 25.94%[4] - The total profit for the third quarter was ¥58,722,638.31, reflecting a significant increase of 53.98% compared to the same period last year[4] - The net profit attributable to shareholders for the third quarter was ¥46,327,956.87, up 44.71% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥43,295,471.69, showing a substantial increase of 79.40% compared to the previous year[4] - Total operating revenue for the first three quarters of 2025 reached ¥979,111,093.03, a 20.7% increase from ¥811,377,889.62 in the same period of 2024[22] - Net profit for the first three quarters of 2025 was ¥119,734,016.41, representing a 42.8% increase compared to ¥83,853,892.80 in the previous year[23] - Basic and diluted earnings per share for the first three quarters of 2025 were both ¥1.37, up from ¥0.94 in the same period of 2024[24] - The basic earnings per share for the third quarter were ¥0.54, reflecting an increase of 54.29% compared to the same period last year[5] - The company reported a total comprehensive income of ¥121,680,002.04 for the first three quarters of 2025, compared to ¥87,226,599.54 in the previous year[24] Assets and Liabilities - The total assets of the company at the end of the reporting period were ¥2,562,961,700.00, an increase of 5.99% from the end of the previous year[5] - As of September 30, 2025, the total assets of the company amounted to RMB 2,562,961,700, an increase from RMB 2,418,035,118.40 as of December 31, 2024, representing a growth of approximately 5.95%[16] - Total liabilities increased to ¥560,499,333.57, compared to ¥390,912,654.76 in the previous year, reflecting a significant rise in financial obligations[18] - Total equity attributable to shareholders decreased to ¥2,002,462,366.43 from ¥2,027,122,463.64 year-over-year[19] - The company's total current assets reached RMB 2,369,501,774.04, compared to RMB 2,208,723,169.25, which is an increase of about 7.29%[17] Cash Flow - The cash flow from operating activities for the year-to-date period was ¥8,732,704.38, which decreased by 91.32% year-on-year[4] - Cash flow from operating activities for the first three quarters of 2025 was ¥929,154,255.85, compared to ¥826,956,332.59 in the same period of 2024[25] - Operating cash inflow totaled $997,205,055.86, an increase of 12.1% from $889,986,877.02[26] - Operating cash outflow amounted to $988,472,351.48, up from $789,436,921.65, resulting in a net cash flow from operating activities of $8,732,704.38, down 91.3% from $100,549,955.37[26] - Cash inflow from investment activities reached $3,368,193,225.84, significantly higher than $360,254,145.57, while cash outflow was $3,486,621,789.06, leading to a net cash flow from investment activities of -$118,428,563.22[26] - Cash inflow from financing activities was $279,935,276.04, compared to $112,168,202.17, while cash outflow totaled $309,855,510.11, resulting in a net cash flow from financing activities of -$29,920,234.07[27] - The net increase in cash and cash equivalents was -$142,884,310.18, compared to -$386,156,614.74 in the previous period[27] - The ending balance of cash and cash equivalents stood at $953,736,388.07, up from $878,913,439.70[27] Shareholder Information - The company reported a total of 3,493 common shareholders at the end of the reporting period[12] - The company has a shareholding structure with significant stakes held by various investment partnerships, including 5,019,806 shares held by Zhoushan Xinxin Enterprise Management Partnership[14] - The company has a total of 4,730,172 shares repurchased, representing 5.20% of its total shares, which may indicate a strategy to enhance shareholder value[14] - The company has not reported any significant changes in the participation of major shareholders in margin financing or securities lending activities[14] Research and Development - Research and development expenses totaled ¥16,038,057.40 for the quarter, accounting for 4.56% of operating revenue, a decrease of 0.98 percentage points year-on-year[5] - Research and development expenses for the first three quarters of 2025 were ¥46,034,736.98, slightly up from ¥45,523,716.19 in the previous year[22] Financial Statements and Accounting - The company’s financial statements for the reporting period are unaudited, indicating a need for caution in interpreting the financial data[15] - The company will implement new accounting standards starting in 2025, which may affect the financial statements[28] Other Financial Metrics - Financial expenses recorded a loss of ¥7,098,512.41, contrasting with a gain of ¥5,325,990.16 in the same period of 2024[23] - The company received tax refunds of $40,429,228.34, compared to $37,423,828.32 in the previous period[26] - The company paid $134,615,488.48 in employee compensation, an increase from $127,648,964.92[26] - The company reported a decrease in tax payments to $38,142,548.69 from $53,293,563.62[26]